Aclarion (ACON) shares rallied sharply early Monday after the healthcare technology company said it has established a commercial agreement with Scripps Health that will add its Nociscan technology platform to treat lower back pain to Scripps facilities in San Diego.
The agreement is expected to optimize Scripps' clinical treatment by providing Aclarion's magnetic resonance spectroscopy signal processing and allowing physicians to non-invasively distinguish between lumbar discs causing pain and non-painful discs, the companies said.
Financial terms were not disclosed.
Aclarion shares climbed by more than 125% in early trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。